Recombinomics | Elegant Evolution






Home Founder What's New In The News Consulting





























H1N1 Consulting

Paradigm Shift

Viral Evolution

Intervention Monitoring

Vaccine Screening

Vaccine Development

Expression Profiling

Drug Discovery

Custom Therapies

Patents 



Audio:Nov30 Dec20 Jan17 Jan24 RSS Feed twitter News Now                         

Commentary

Alarming US Week 3 P&I  Death Rate Spike to 9.8%
Recombinomics Commentary 17:00
January 25, 2013

Week 3 P&I Spike

The above CDC FluView week 3 Pneumonia & Influenza graph displays the dramatic spike created by the jump from 7.3% to 8.3% in week 2 followed by a jump to 9.8% in week 3.  As seen above the 9.8% level has not been seen in the prior years displayed and which is also true for the steep slope.  The 9.8% level is the highest seen since 2003, when an H3N2 strain, A/Fujian/411/2002, produced a large number of deaths in those over 65 as well as an alarming pediatric death rate.  Subsequent regulations precipitated by the 2003-04 season made lab confirmed pediatric deaths reportable in the United States.  The week 9.8% P&I rate was also associated with 36 cities which had at least 10 P&I deaths and a rate of 10% or higher, including six cities with a rate above 20%.

Although some states have reported a slowing or decline in hospitalizations and deaths, it remains unclear if the flu season has peaked, Flu rates historically increase in January and February in the northern hemisphere and the P&I baseline graph peaks in week 10.  The week 3 FluView reports 8 more pediatric deaths, raising the total to 37.  However, 13 additional cases have been cited in media or state lab reports. 

In addition, the graph of the hospitalization rate continues to rise, especially for those over 65.

Media Link

Recombinomics Presentations

Recombinomics Publications

Recombinomics Paper at Nature Precedings















Home | Founder | What's New | In The News | Contact Us

Webmaster: webmaster@recombinomics.com
© 2013 Recombinomics.  All rights reserved.